Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations

(NYSE MKT: VTAK), FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine months ended September 30, 2025. Highlights of the quarter and nine months include: Financial […]

Innventure Reports Third Quarter 2025 Results

(NasdaqGM:INV),(NASDAQ:INVW), Accelsius recently secured strategic investment from Johnson Controls and introduced its NeuCool(R) MR250 system; pipeline of opportunities now exceeds $1 billion AeroFlexx delivered 5th consecutive quarter of revenue generation with growing customer pipeline in U.S. and Europe Refinity on track to demonstrate pilot scale and finalize initial site selection for first plant by year-end

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

(Paris:NANO),(NASDAQ: NBTX), Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborations New in vivo pre-clinical data evaluating the Nanoprimer in combination with therapeutic vaccines were presented at the 2025 Partnership Opportunities in Drug

DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025

(TSX-V:ADK),(OTC US:DGNOF),(Other OTC:DGNOF),(Frankfurt:4D4A), BROSSARD, Quebec, Nov. 13, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 3,502,931

SAIC Announces Organizational Changes Intended to Simplify Structure, Sharpen Focus and Deliver Sustainable Long-Term Growth and Shareholder Value Creation

(NASDAQ:SAIC), Highlights: Five existing business groups will be consolidated into three business groups The consolidated business groups are Army Navy (ANG); Air Force, Space and Intelligence (AFSI); and Civilian The restructured organization is aimed at optimizing the company's operations and customer focus for growth and shareholder value creation The new organizational structure will be effective

Inno Holdings Inc. Announces $50 Million “At-the-Market” Equity Offering Program

(NASDAQ:INHD), HONG KONG, Nov. 13, 2025 (GLOBE NEWSWIRE) — Inno Holdings Inc. (NASDAQ: INHD) (the “Company”), a trade-focused building technology and electronic products trading company, today announced that it has entered into an At-the-Market (“ATM”) equity offering sales agreement (the “Agreement”) under which the Company may, from time to time, offer and sell shares of

Caliber Reports Third Quarter 2025 Financial Results

(NASDAQ:CWD), SCOTTSDALE, Ariz., Nov. 13, 2025 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today reported results for the third quarter ended on September 30, 2025. Third Quarter 2025 Highlights Raised more than $30.0 million through common and preferred equity, strengthening Caliber's balance sheet and liquidity. Launched Caliber's

United Community Banks, Inc. Announces Quarterly Cash Dividend On Common Stock

(NYSE:UCB),(NYSE:UCB-PI), GREENVILLE, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (“United”, the “Company”), reported that its Board of Directors approved a quarterly cash dividend of $0.25 per share on the Company's common stock. The dividend is payable on January 5, 2026 to shareholders of record as of December 15, 2025.

Astrotech Reports First Quarter of Fiscal Year 2026 Financial Results

(NASDAQ:ASTC), AUSTIN, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the first quarter of fiscal year 2026, which ended September 30, 2025. Financial Highlights & Recent Developments Revenue increased to $297 thousand or 35% in the first quarter of fiscal year 2026 as

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress GlobeNewswire November 13, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025, and highlighted

Scroll to Top